
    
      Exalenz has previously gathered information in a previous study on patients with chronic
      liver disease including the methacetin breath test. Several years later, the company wishes
      to investigate this group of subjects and see retrospectively if the breath test was a
      predictor of complications related to their liver disease.
    
  